Skip to main content
OpenTrials
Completed

NCT Number: NCT02634450

Early Infant Diagnosis Point of Care Pilot

In Mozambique, early infant HIV diagnosis (EID, i.e. HIV screening of infants under 18 months of age) is conducted using molecular diagnostics at central laboratories in Maputo, Nampula, Beira and Quelimane. However, test volumes are growing and many parts of the country do not have close access to laboratories. Test samples are transported over large distances and this can introduce testing delays, especially for patients in rural and remote areas of the country. There are now new POC EID technologies becoming available that will enable diagnosis of HIV in infants within minutes or a couple of hours on site in the clinic, operated by non technical staff and without laboratory infrastructure. This protocol describes a plan to conduct an evaluation of a Point-Of-Care (POC) Early Infant Diagnosis (EID) testing technologies that are being considered for use in Mozambique, and to pilot those technologies in order to provide more effective diagnostics and clinical care to patients. During this implementation pilot, sites are randomized to use either conventional or POC EID testing only before the inclusion of the patients in the study. No consent will be asked to the parents or guardians. A written permission will be asked to the Direção Provincial de Saúde of both provinces to implement the POC device as routine in those intervention sites. All the information that will be analyzed will be collected from the routine care and it will be analyzed as a group.

Completed

Looking for future studies?

Notify Me

Key information

Age range

4 week–18 month

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centro de Saude Moamba, Moamba, Maputo Province, Mozambique

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Born to HIV positive mother
  • From 4 weeks to 18 months of age
  • Came to CCR consultation for Early Infant Diagnosis

Exclusion criteria

  • With a valid positive test by other center

Treatment and study plan

Alere q

Device

Primary outcomes

  1. The proportion of HIV-positive infants initiating antiretroviral therapy within 60 days of sample collection

    Time frame: up to 6 months

  2. the proportion of HIV-positive infants who initiated antiretroviral therapy that were retained in care at 90 days of follow-up.

    Time frame: 3 months after treatment initiation

    Patients were considered retained in care at 90 days if they had visited the health facility within the previous 30 days.

Secondary outcomes

  1. The median age at time of results received by patient

    Time frame: Up to 6 months

  2. The median number of days between specimen collection and results received by patient

    Time frame: Up to 6 months

  3. The median age at time of antiretroviral treatment initiation

    Time frame: Up to 6 months

  4. The median number of days between specimen collection and initiation of antiretroviral treatment.

    Time frame: Up to 6 months

Sponsors and collaborators

Lead sponsor

Instituto Nacional de Saúde, Mozambique

Other Gov

Collaborators

  • Clinton Health Access Initiative Inc.
  • UNICEF
  • UNITAID

Registry information

Official study title

Evaluation of Point-Of-Care Testing Assays for Early Infant in Mozambique-Cluster Randomised Trial

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Dec 18, 2015
Registry last updated
Jul 26, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.